Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.78 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.78 |
| ▸ | MRGPRX2 | Q96LB1 | 5/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642989 | 1.00 | OPRM1 (0.78) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| SCHEMBL20306854 | 1.00 | OPRM1 (0.78) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| SCHEMBL46251 | 1.00 | OPRM1 (0.78) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| SCHEMBL10045461 | 0.89 | OPRM1 (0.81) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| SCHEMBL12030889 | 0.89 | OPRM1 (0.81) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12091243 | 0.88 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL19199030 | 0.88 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL16015635 | 0.88 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL38920 | 0.88 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12230555 | 0.88 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736889-B2 | Method of treating dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180185355-A1 | Method of Treating Dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-07-05 | — | — | US | disclosed |
| US-20180185355-A1 | Method of Treating Dyskinesia | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185355-A1 | Method of Treating Dyskinesia | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 2/4885 |
| US-10736889-B2 | Method of treating dyskinesia | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRK1 2/4885OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.